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Abstract
Background: There is a marked lack of evidence on the optimal prevention of ischaemic stroke and other
thromboembolic events in patients with non-valvular atrial fibrillation and a recent intracerebral haemorrhage
during treatment with oral anticoagulation. These patients are currently treated with oral anticoagulants, antiplatelet
drugs, or no antithrombotic treatment, depending on personal and institutional preferences.
Compared with warfarin, the direct oral anticoagulant apixaban reduces the risk of stroke or systemic embolism,
intracranial haemorrhage, and case fatality in patients with atrial fibrillation. Compared with aspirin, apixaban
reduces the risk of stroke or systemic embolism in patients with atrial fibrillation, and has a similar risk of
intracerebral haemorrhage. Novel oral anticoagulants have not been evaluated in patients with atrial fibrillation and
a recent intracerebral haemorrhage.
To inform a phase III trial, the phase II Apixaban versus Antiplatelet drugs or no antithrombotic drugs after
anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF) trial aims to
obtain estimates of the rates of vascular death or non-fatal stroke in patients with atrial fibrillation and a recent
anticoagulation-associated intracerebral haemorrhage treated with apixaban and in those in whom oral
anticoagulation is avoided.
Methods/Design: APACHE-AF is a phase II, multicentre, open-label, parallel-group, randomised clinical trial with
masked outcome assessment. One hundred adults with a history of atrial fibrillation and a recent intracerebral
haemorrhage during treatment with anticoagulation in whom clinical equipoise exists on the optimal stroke
prevention strategy will be enrolled in 14 hospitals in The Netherlands.
These patients will be randomly assigned in a 1:1 ratio to either apixaban or to avoiding oral anticoagulation.
Patients in the control group may be treated with antiplatelet drugs at the discretion of the treating physician. The
primary outcome is the composite of vascular death or non-fatal stroke during follow-up. We aim to include 100
patients in 2.5 years. All patients will be followed-up for the duration of the study, but at least for 1 year.
(Continued on next page)
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Background
Stroke is a major cause of death and disability and is
associated with high healthcare expenditure [1, 2].
About 80 % of strokes are ischaemic, 15 % intracere-
bral haemorrhage (ICH), and 5 % subarachnoid
haemorrhage [3].
Cardioembolism, most often caused by non-valvular
atrial fibrillation (AF), accounts for 13 to 27 % [4, 5] of
ischaemic strokes. The average annual risk of ischaemic
stroke in patients with AF not treated with antithrom-
botic drugs is 4.5 % [6]. The risk of ischaemic stroke can
be estimated with the CHA2DS2-VASc score [7]. The an-
nual thromboembolic event rate increases from 2.2 %
with a CHA2DS2-VASc score of 2 to 15.2 % with the
maximum score of 9 [8]. In patients with AF and a
CHA2DS2-VASc score ≥ 1, treatment with an oral anti-
coagulant (OAC) is recommended [9, 10]. Traditionally,
vitamin K antagonists (VKA) have been the first choice
for prevention of thromboembolic events in these pa-
tients. While VKA therapy decreases the risk of ischae-
mic stroke, it increases the risk of ICH, the most
devastating complication of OAC therapy. The risk of
ICH in patients with AF treated with vitamin K antago-
nists is 0.3 to 3 % per year, and increases with increasing
age [11–14]. This complication leads to death in 45 % of
cases, and only 17 % of patients recover without disabil-
ity [15].
In patients with AF who are unsuitable for VKA therapy
because of poor compliance or allergy, or who are unwill-
ing to receive this therapy, antiplatelet drugs (APDs, e.g.
acetylsalicylic acid, clopidogrel) may be considered [9, 10].
However, antiplatelet treatment only results in a modest
reduction in the risk of ischaemic stroke [16] and in-
creases the risk of major bleeding as compared to no anti-
thrombotic therapy (incidence rate ratio 1.55; 95 %
confidence interval (CI), 1.48–1.63)) [17].
In patients with AF who survive an anticoagulation-
related ICH, a longstanding and pressing clinical di-
lemma is whether or not to resume treatment with oral
anticoagulation to prevent ischaemic stroke and other
future thrombotic and embolic complications [18, 19].
Randomised trials have not been performed and reliable
estimates of the risk of recurrent ICH or ischaemic
stroke after resumption of antithrombotic drugs on the
one hand, or permanent discontinuation of these drugs
on the other, are lacking [20].
Patients with AF on warfarin who survive an ICH have
a higher event rate for the combination of ischaemic
stroke, systemic embolism or transient ischaemic attack
in the 2 years following the ICH compared with AF pa-
tients on warfarin who did not experience an ICH (event
rate ratio, 5.40 (95 % CI 4.04 to 7.22) [21].
In retrospective studies of small patient cohorts, the
annual risk of recurrent ICH after resumption of VKAs
varied between 2.5 and 20 % and that of ischaemic
stroke between 0 and 33 % [22–26]. In patients in whom
VKAs were discontinued permanently, the risk of ICH
varied between 0 and 9 % and the risk of ischaemic
stroke between 10 and 48 % [22–26].
In small observational studies of patients who survived
an ICH – regardless of whether this occurred during the
use of a VKA – no difference was found in the risk of re-
current ICH between patients treated with acetylsalicylic
acid after the initial ICH and those who used no anti-
thrombotic drugs [25, 27–29], with an annual risk of re-
current ICH between 2.3 and 8.2 % [27, 29]. The annual
risk of ischaemic stroke in these patients varied between
1.3 and 9.4 %.
The above-mentioned estimates for the risk of ischae-
mic stroke or recurrent ICH during treatment with VKA
or APD are not reliable because of selection bias, the in-
clusion of patients with different indications for the use
of antithrombotic drugs, and variation in target inter-
national normalised ratios (INRs). In addition, estimates
varied widely between studies and had wide CIs because
of the small numbers of patients included.
The aforementioned information illustrates that there
is a need for evidence-based recommendations for the
prevention of stroke and other thromboembolic com-
plications in survivors of anticoagulation-related ICH
[30, 31]. Currently, patients are treated – based on ‘expert
opinion’ – with OAC, APDs, or no antithrombotic medi-
cation at all, resulting in marked practice variation [32].
In the past few years, novel, direct anticoagulant drugs
(DOACs) have been introduced in clinical practice.
These drugs reduce coagulation by inhibition of factor
Xa (rivaroxaban, apixaban and edoxaban) or factor IIa
(dabigatran), resulting in a reduced thrombin generation,
diminished enzymatic conversion of fibrinogen to fibrin
and, thus, less efficient clot formation.
In the randomised Apixaban for Reduction in Stroke
and Other Thromboembolic Events in Atrial Fibrillation
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(ARISTOTLE) study, the oral factor Xa inhibitor apixaban
at a dose of 5 mg twice daily was more effective than war-
farin (target INR, 2.0 to 3.0) in preventing stroke or sys-
temic thromboembolism in patients with AF: hazard ratio,
0.79; 95 % CI, 0.66 to 0.95; P < 0.001 for non-inferiority;
P = 0.01 for superiority. Patients treated with apixaban less
often had an ICH (hazard ratio, 0.51; 95 % CI, 0.35 to
0.75; P < 0.001) than patients treated with warfarin [33].
These beneficial effects were seen throughout different
times in therapeutic range (TTR) ranges [34].
Of the DOACs, only apixaban has been compared
with acetylsalicylic acid in a randomised controlled
trial in patients with AF. In the trial Apixaban Versus
Acetylsalicylic Acid to Prevent Stroke in Atrial Fibril-
lation Patients Who Have Failed or Are Unsuitable
for Vitamin K Antagonist Treatment (AVERROES),
patients with AF who were treated with apixaban 5
mg twice daily had a lower risk of stroke or systemic
embolism than patients treated with acetylsalicylic
acid at a dose of 81 to 324 mg per day (hazard ratio
0.45; 95 % CI 0.32 to 0.62; P < 0.001), whereas the
rates of ICH in the 2 groups were similar [35].
In phase III randomised trials comparing other
DOACs with warfarin in patients with AF, these were
non-inferior to warfarin in the prevention of stroke and
systemic embolism and were associated with a reduced
risk of intracranial bleeding [36–38].
In a meta-analysis of phase III randomised trials
of patients with AF who were randomised to receive
DOACs or warfarin, the DOACs had a favourable
risk-benefit profile, with significant reductions in
stroke, intracranial haemorrhage, and mortality, and
with a similar major bleeding risk as for warfarin, but
an increased risk of gastrointestinal bleeding. The
relative efficacy and safety of DOACs was consistent
across a wide range of patients [39].
The DOACs have not been compared against each
other in clinical trials. A meta-analysis using a Baysian
random effects model suggested that the risk reductions
for ICH as compared to warfarin are similar [40]. There
are no clinical trials testing the effect of a DOAC in pa-
tients with AF and a recent oral anticoagulant-associated
intracerebral haemorrhage (OAC-ICH).
We hypothesise that in patients with AF who sur-
vived an anticoagulation-associated ICH, treatment
with apixaban may be the best long-term alternative for
the prevention of recurrent stroke and systemic thrombo-
embolism. To test this hypothesis, a conclusive phase III,
randomised clinical trial comparing the long-term effects
of apixaban with those of APDs or no antithrombotic
treatment in these patients is required. Before such a
trial can commence, a phase II trial is needed to ob-
tain reliable estimates of the rates of vascular death or
non-fatal stroke for both strategies in patients with AF
and a recent anticoagulation-associated ICH. As a
secondary objective, we aim to compare the rates of
all-cause death, vascular death, stroke, ischaemic
stroke, recurrent ICH, other major haemorrhage, sys-
temic embolism, myocardial infarction, and functional
outcome between patients treated with apixaban and
those in whom anticoagulation is avoided.
Rationale for study treatment
The treating physician will decide on any of the treat-
ment regimens in the comparator group. This design
is based on the lack of evidence that any of the treat-
ment options has a more favourable risk-benefit ratio
in this population than others [18, 32, 41, 42].
Allowing variable treatment regimens enables us to in-
clude patients with or without a medical history of athero-
sclerotic disease, which could warrant the use of APDs.
The choice for these treatment options in the comparator
arm enables us to achieve close similarity with current
clinical practice and include as many eligible patients as
possible to answer the research question.
The physician can include other indications for APDs
(e.g., a history of myocardial infarction) in the decision
on the treatment in the comparator arm.
Treatment with any of the drugs in the study can com-
mence anywhere between 7 and 90 days after the ICH,
at the discretion of the treating physician. There are re-
ports suggesting that VKAs can be resumed after 3 days
[43], whereas others recommend resumption of anti-
thrombotic drugs anywhere between 70 and 210 days, if
at all [24]. In the absence of evidence on the optimal
timing of the resumption of antithrombotic drugs after
ICH, we chose this interval as it reflects clinical practice.
Methods/Design
Overview
APACHE-AF (Fig. 1, http://www.apache-af.nl) is a phase
II, randomised, open-label, parallel-group, multicentre
clinical trial with masked outcome assessment (PROBE
design [44]), comparing apixaban and avoiding anticoagu-
lation in patients with AF and a recent anticoagulation-
associated ICH. An adjudication committee blinded to
treatment allocation will adjudicate outcomes.
A total of 100 patients will be included in 7 academic and 8
regional hospitals in the Netherlands over a period of 2.5
years. Members of the various study committees are listed in
Appendix 1. Follow-up will continue until 1 year after inclu-
sion of the last patient. The total study period is expected to
be 4 years. Patient recruitment has started in September 2014.
Eligible patients
Patients with AF who recently had an ICH during the use
of anticoagulation, in whom there is clinical equipoise
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regarding the optimal medical treatment for the prevention
of stroke, are eligible for participation in this trial. The ICH
should have occurred between 7 and 90 days prior to ran-
domisation. The CHA2DS2-VASc score should be 3 or
higher [8] and the score on the modified Rankin Scale
(mRS) [45], as a measure for disability, 4 or lower. Detailed
eligibility criteria are shown in Table 1.
Randomisation
Allocation to treatment groups will be based on ran-
domisation through a web-based system. Treatment al-
location will be stratified by the choice of treatment in
the comparator arm (APD versus no APD) and will use
a minimisation algorithm for age (≤75 years versus >75
years) and location of the haemorrhage (lobar versus
non-lobar). This treatment allocation ensures that both
treatment groups will be comparable with regard to the
intended treatment in the comparator arm.
Intervention
Patients will be randomised to treatment with apixaban
5 mg or 2.5 mg given orally twice daily, or to treatment
with one or two oral APDs (acetylsalicylic acid, carbasa-
late calcium, clopidogrel, or dipyridamole) or no anti-
thrombotic treatment at all, at the discretion of the
treating physician. Details about the allowed treatments
in both groups are shown in Table 2. Treatment will
start immediately after randomisation and will continue
for the duration of the study. If during the course of a
patient’s participation in this study the treating physician
feels that a particular antithrombotic drug is clearly indi-
cated or contra-indicated, the choice of the antithrom-
botic drug may be changed.
Patients in both treatment groups will be treated ac-
cording to the relevant guidelines for the prevention of
stroke or systemic embolism.
Study parameters
We will collect the following parameters: 1) information
about the index ICH, including date, National Institutes
of Health Stroke Scale score [46], location and volume
of the ICH assessed on computed tomography (CT) or
magnetic resonance imaging (MRI), antithrombotic
medication and INR; 2) previous medical history, includ-
ing cardiovascular risk factors and previous cardiovascular
events, and all variables comprising the CHA2DS2−VASc [8]
and HAS-BLED [47] scores; 3) blood levels of haemoglobin,
liver enzymes, and creatinine, and calculated glomerular filtra-
tion rate; 4) at the time of randomisation: the score on the
mRS, blood pressure, and the Informant Questionnaire on
Cognitive Decline in the Elderly (IQCODE), to screen for
cognitive decline prior to the index ICH [48].
Study procedures
After written informed consent will have been obtained,
the patient will be randomised. We will collect imaging
data obtained in routine clinical care for central reading.
At inclusion, the IQCODE will be administered to a per-
son who is close to the patient (partner, family member
or friend).
After randomisation, the patient will receive written
information related to the assigned treatment to maxi-
mise treatment adherence, consisting of a patient alert
card for this trial in general and a specific patient alert
card for apixaban users. The investigator will send a let-
ter to the general practitioner that will mention inclu-
sion in this trial.
At 1 (±7 days), 6 (±14 days), and 12 (±28 days) months
and subsequently every 12 months (±28 days), follow-up
visits will be scheduled (Fig. 2).
The treating physician or his representative will per-
form each follow-up visit. Patients will be asked to fill
out the Modified Morisky Scale [49] for treatment ad-
herence. Blood pressure will be measured. Disability will
be measured with the mRS. Patients will be questioned
about the occurrence of outcome events or (other) ser-
ious adverse events (SAEs) in the preceding period.
Study outcomes
The primary outcome is the combination of vascular
death or non-fatal stroke (cerebral infarction, ICH, or
subarachnoid haemorrhage) during follow-up. Secondary
outcomes will be: vascular death, death from any cause,
Fig. 1 Trial logo
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all stroke, ischaemic stroke, ICH, other major extracra-
nial haemorrhage, any intracranial haemorrhage other
than ICHd, systemic embolism, myocardial infarction,
and functional outcome as assessed with the score on
the mRS at 6 and 12 months; annually thereafter; and at
the end of the study. Definitions of the clinical events
comprising the study outcomes are shown in Table 3.
Outcome adjudication
An outcome adjudication committee will adjudicate new
outcomes on a regular interval. This committee will con-
sist of two experienced vascular neurologists and an ex-
perienced cardiologist. The committee will receive
outcome information blinded to patient identifiers and
treatment allocation.
Sample size estimation
For the population under study, there are no reliable es-
timates of the occurrence of the primary outcome for
each of the tested treatments, and the main aim of this
study is, therefore, to obtain such estimates to inform
the design of a phase III clinical trial. Inclusion of a total
of 50 patients in each of the treatment arms during the
first 30 months of the study and 1 final year of follow-up
will result in about 100 patient-years of follow-up in
each treatment arm. Ten primary outcome events in 100
patient-years of follow-up will yield a 95 % CI of 4.9 to
17.6. This estimate will not only be more reliable be-
cause selection bias will not play a major role in this
phase II trial, but also be more precise in comparison
with the previous retrospective cohort studies.
Statistical analysis
The primary analysis will be based on the intention-to-
treat principle. As a secondary analysis, we will perform
a per-protocol analysis for the primary study outcome.
Before the end of the study, a final statistical analysis
plan will be completed.
The occurrence of the primary outcome (occurrence
of vascular death or a non-fatal stroke) in each of the 2
treatment groups will be expressed as an annual event
rate with a 95 % CI. The occurrence of the primary out-
comes between the 2 treatment groups will be reported
in terms of the hazard ratio with corresponding 95 %
CIs, calculated with the Cox proportional hazard model.
The effect of the allocated treatment on the various
other outcome events and SAEs will be assessed in the
same fashion as the primary study parameter.
We will dichotomise the mRS scores at follow-up into
3 to 6 (poor outcome) and 0 to 2 (good outcome). The
effect of the treatment on the mRS will be analysed
using risk ratios with a corresponding 95 % CI.
Table 1 Eligibility criteria
Inclusion criteria
Intracerebral haemorrhage (including isolated spontaneous
intraventricular haemorrhage), documented with CT or MRI, during
treatment with anticoagulation (VKA, any direct thrombin inhibitor, any
factor Xa inhibitor, or (low-molecular-weight) heparin at a therapeutic
dose)
The haemorrhage has occurred between 7 and 90 days before
randomisation
Diagnosis of (paroxysmal) non-valvular AF, documented on
electrocardiography
A CHA2DS2-VASc score ≥ 3
Score on the modified Rankin Scale (mRS) [45]
Equipoise regarding the optimal medical treatment for the prevention
of stroke. The clinical equipoise should be self-reported by the attending
neurologist after reviewing all relevant information available for the indi-
vidual patient
Age ≥ 18 years
Written informed consent by the patient or by a legal representative
Exclusion criteria
Conditions other than AF for which the patient requires long-term
anticoagulation
A different clinical indication for the use of an antiplatelet drug even if
treated with apixaban, such as clopidogrel for recent coronary stenting
Mechanical prosthetic heart valve (biological prosthetic heart valves are
allowed) or rheumatic mitral valve disease
Serious bleeding event in the previous 6 months, except for
intracerebral haemorrhagea
High risk of bleeding (e.g. active peptic ulcer disease, a platelet count of
< 100,000 per ml or haemoglobin level of < 6.2 mmol L-1 ischaemic
stroke in the previous 7 days (patients are eligible thereafter),
documented haemorrhagic tendencies, or blood dyscrasias)
Current alcohol or drug abuse
Life expectancy of less than 1 year
Severe renal insufficiency (a serum creatinine level of more than 221
μmol L-1 or a calculated creatinine clearance of < 15 ml per minute)
Alanine aminotransferase or aspartate aminotransferase level greater
than twice the upper limit of the normal range or a total bilirubin more
than 1.5 times the upper limit of the normal range, unless a benign
causative factor (e.g. Gilbert’s syndrome) is known or identified
Allergy to apixaban
Use of strong cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp)
inhibitors (e.g. systemic azole-antimycotics such as ketoconazole or HIV
protease inhibitors such as ritonavir)
Pregnancy or breastfeeding
Women of childbearing potential: any woman who has begun
menstruation and is not postmenopausal or otherwise permanently
unable to conceive. A postmenopausal woman is defined as a woman
who is over the age of 45 and has not had a menstrual period for at
least 12 months
aSerious bleeding event: see major extracranial haemorrhage and clinically
relevant non-major bleeding in Table 3
AF atrial fibrillation, CT computed tomography, MRI magnetic resonance
imaging, VKA vitamin K antagonist
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We will adjust the crude hazard ratios and risk ratios
for possible baseline incomparability given the size of
the study.
Interim analyses
Interim analyses on safety and efficacy will be performed
by the Data Safety and Monitoring Board (DSMB) ac-
cording to the DSMB charter. These analyses are per-
formed after 50, 100, and 150 patient-years of follow-up,
and ad hoc as needed.
The interim analyses on both safety and efficacy will be
performed on the primary outcome: the occurrence of
vascular death or non-fatal stroke. This combined out-
come consists of both the main efficacy outcome (ischae-
mic stroke) events as well as the main outcomes for harm
(ICH, fatal vascular event).
The DSMB will compare both treatment arms using a
Poisson’s test (Conditional Test) with two-sided testing.
For all interim analyses of the primary outcome, a
boundary of P < 0.01 will be used for any recommenda-
tion to terminate the trial.
Subject withdrawal
Subjects can leave the study at any time for any reason if
they wish to do so without any consequences. The inves-
tigator or the treating physician can decide to withdraw
a subject from the study for urgent medical reasons.
Subjects will not be replaced after withdrawal. In pa-
tients who discontinue their allocated treatment, this
event will be recorded, including the reason for discon-
tinuation and the new treatment strategy. After discon-
tinuation of the study treatment, follow-up will be
carried out as planned.
Data Safety and Monitoring Board
An independent Data Safety Monitoring Board (DSMB),
consisting of a neurologist, a cardiologist, and a biostat-
istician, monitors the safety and efficacy of the study.
See Additional file 1 for the DSMB charter.
Monitoring
This study has a moderate risk based on the risk classifi-
cation of the Dutch Federation of University Medical
Centres [50], and will be monitored accordingly. The
monitoring plan is attached as Additional file 2.
Safety reporting
Adverse events are defined as any undesirable experi-
ence occurring to a subject during the study, whether or
not considered related to the allocated treatment. All
adverse events reported spontaneously by the subject or
observed by the investigator or his staff will be recorded
in the medical record on site. Only (suspected)
Table 2 Possible treatments in both trial arms
Arm 1: apixaban Arm 2: avoid anticoagulation
Apixaban 5 mg twice daily No antithrombotic treatment
Apixaban 2.5 mg twice dailya Acetylsalicylic acid 80 mg once daily
Carbasalate calcium 100 mg once daily
Clopidogrel 75 mg once daily
Acetylsalicylic acid 80 mg once daily and dipyridamole 200 mg twice daily
Carbasalate calcium 100 mg once daily and dipyridamole 200 mg twice daily
aReduced dose: the dose will be reduced if 2 of the 3 following criteria are met: age ≥ 80 years, body weight ≤ 60 kg or serum creatinine ≥133 μmol. If the
creatinine clearance is below 30 ml per minute, the dose will also be reduced
Fig. 2 Flowchart of study procedures
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thromboembolic or haemorrhagic adverse events and all
SAEs will be reported to the sponsor.
A SAE is any untoward medical occurrence or effect
that at any dose:
 results in death
 is life threatening (at the time of the event)
 requires hospitalisation or prolongation of existing
inpatients’ hospitalisation
 results in persistent or significant disability or
incapacity
 is a congenital anomaly or birth defect
Any other important medical event that may not result
in death, be life threatening, or require hospitalisation,
may be considered a serious adverse experience when,
based upon appropriate medical judgement, the event
may jeopardise the subject or may require an interven-
tion to prevent one of the outcomes listed above.
Patients, their partners or families, as well as their
general practitioner are requested to report any possible
SAE as soon as possible to the local investigator. If the
Table 3 Event definitions
Ischaemic stroke Clinical evidence of the sudden onset of a new neurological deficit, or an increase in an existing deficit, persisting for
more than 24 hours, without evidence of a intracerebral haemorrhage on a CT or MRI scan or at post-mortem
investigation
Intracerebral haemorrhage Clinical evidence of the sudden onset of a new neurological deficit, or an increase in an existing deficit, persisting for
more than 24 hours, with a corresponding intracerebral haemorrhage on a CT or MRI scan or at post-mortem
investigation
Unclassified stroke Clinical evidence of the sudden onset of a new neurological deficit, or an increase in an existing deficit, persisting for
more than 24 hours, without imaging or post-mortem investigations performed
Subarachnoid haemorrhage Subarachnoid haemorrhage (SAH) demonstrated by CT, lumbar puncture, or at post-mortem investigation
Myocardial infarction Evidence of myocardial necrosis in a clinical setting consistent with acute myocardial ischemia. Under these
conditions any one of the following criteria meets the diagnosis for MI [51]:
● Detection of a rise and/or fall of cardiac biomarker values (preferably cardiac troponin) with at least one value
above the 99th percentile upper reference limit and with at least one of the following:
○ Symptoms of ischemia
○ New or presumed new significant ST-segment-T wave changes or new left bundle branch block (LBBB)
○ Development of pathological Q waves in the ECG
○ Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality
○ Identification of an intracoronary thrombus by angiography or autopsy
● Cardiac death with symptoms suggestive of myocardial ischemia and presumed new ischemic ECG changes or
new LBBB, but death occurred before cardiac biomarkers
Vascular death Death from cerebral infarction; intracerebral, subarachnoid, epidural, or subdural haemorrhage; unclassified stroke;
myocardial infarction; extracranial haemorrhage; or systemic embolism, fatal arterial or gastric bleeding, terminal heart
failure, fatal pulmonary embolism, and sudden death, defined as death within 1 hour after onset of symptoms
Major extracranial
haemorrhage
Major extracranial bleeding will be defined using the ISTH criteria [52];
1) Fatal bleeding, and/or
2) Symptomatic bleeding in a critical area or organ, such as intraspinal, intraocular, retroperitoneal, intra-articular or
pericardial, or intramuscular with compartment syndrome, and/or
3) Bleeding causing a fall in haemoglobin level of 1.24 mmol L−1 or more, or leading to transfusion of 2 or more
units of whole blood or red cells
Clinically relevant non-major
bleeding
Clinically relevant non-major bleeding will be defined as acute clinically overt bleeding that does not satisfy additional criteria
required for the bleeding event to be defined as a major bleeding event and meets at least one of the following criteria [53]:
● Hospital admission for bleeding
● Physician-guided medical or surgical treatment for bleeding
● Change in antithrombotic (anticoagulant or antiplatelet) therapy
Intracranial haemorrhage Intracerebral haemorrhage (see above), SAH (see above), subdural haemorrhage: evidence of a subdural haematoma
on a CT or MRI scan or at post-mortem investigations; epidural haematoma: evidence of an epidural haematoma on
a CT or MRI scan or at post-mortem investigations
Systemic embolism The diagnosis of systemic embolism requires a clinical history consistent with an acute loss of blood flow to a peripheral
artery (or arteries) supported by evidence of embolism from surgical specimens, post-mortem investigations, angiography,
vascular imaging, or other objective testing
CT computed tomography, ECG electrocardiogram, MRI magnetic resonance imaging
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local investigator is notified of a possible SAE or if the
local investigator or his staff detect a possible SAE them-
selves, the local investigator will assess the severity of
the adverse event using the criteria described above.
A local investigator will inform the coordinating inves-
tigators within 24 hours after he has first knowledge of
the event by Email and by filling out the provided SAE
form in the electronic data capture platform. All possible
SAEs will also be recorded in the patients’ medical rec-
ord at the site of the local investigator.
The coordinating investigators will report any SAEs to
the Medical Research Ethics Committee, pursuant to the
Dutch Medical Research Involving Human Subjects Act.
Informed consent
The local investigator will recruit patients. The treating
physician will ask the patient’s or his proxy’s permission
to inform the local investigator.
The patient will be informed in person and receive the
patient information letter and informed consent form.
The first contact with the local investigator will occur
no later than on the 76th day after the ICH. The patient
will be offered all the available time he deems necessary
to consider his decision, but consent by the patient, or
in case of incapacity by the patient’s legal representative,
must be obtained before or on day 90 after ICH. If an in-
capacitated subject regains capacity during the study, he
will be asked to provide informed consent at that time.
Ethical considerations
The study will be conducted according to the principles
of the Declaration of Helsinki (Fortaleza, Brazil, October
2013) and in accordance with the Dutch Medical Re-
search Involving Human Subjects Act and other guide-
lines, regulations and Acts.
The study was approved by the University Medical
Center Utrecht Medical Research Ethics Committee on
26 August 2014.
The objective of this study can only be accomplished in
patients with AF and a recent ICH during treatment with
anticoagulants, as we wish to estimate the annual rates of
vascular outcomes in patients with both AF and a recent
ICH when treated with apixaban and when anticoagula-
tion is avoided. A large proportion of patients who sur-
vived an ICH will be incapacitated due to language or
cognitive deficits. The clinical dilemma addressed above
equally applies to these patients. The inclusion of (tem-
porarily) incapacitated subjects is needed because patients
with the capacity to provide informed consent are likely to
differ from those without this capacity with respect to le-
sion location and size. Results obtained in patients with
the capacity to consent can, therefore, not readily be ex-
trapolated to patients without this capacity.
For all antithrombotic drugs, a recent ICH is a relative
contra-indication to their use and current clinical evi-
dence on this topic is scarce or non-existent. Physicians
currently have to rely on their personal clinical judgment
to weigh the benefits and risks in prescribing or with-
holding any antithrombotic therapy in this group. APDs,
DOACs such as apixaban, VKAs, and withholding anti-
thrombotic drugs are all strategies used by clinicians
today. In this trial, we will include patients in whom
there is equipoise on the optimal antithrombotic
strategy.
Both a previous ICH and antithrombotic therapy are
risk factors for recurrent ICH. There is a risk of recur-
rent ICH or other major bleeding for all participants,
but this is likely to be higher when treated with apixaban
or an APD. Conversely, the risk of ischaemic stroke or
other thrombo-embolism is increased in patients in
whom antithrombotic therapy is withheld. The risk-
benefit ratios of all proposed treatments are uncertain.
Apixaban use is a contra-indication for intravenous
thrombolysis for acute ischaemic stroke. Patients using
apixaban, therefore, cannot be treated with thrombolysis
in case of ischaemic stroke during follow-up. However,
the risk of ischaemic stroke in patients treated with apix-
aban will most likely be lower than in patients without
antithrombotic therapy or treated with APD and, there-
fore, we consider this potential disadvantage of apixaban
acceptable.
Aside from the bleeding risk, participants allocated to
the use of apixaban or an APD are exposed to other side
effects of these drugs. The risks of these other side ef-
fects are limited.
Investigators will follow their local protocols regarding
the management of bleeding in patients using apixaban.
Such protocols are available at each study site.
Because both drugs are currently used in this group of
patients without any reliable evidence for their net bene-
fit, and because we only include patients in whom clin-
ical equipoise with regard to the optimal treatment
strategy exists, we feel we do not expose participants to
a significant additional risk in participating in this study
compared with current clinical practice.
Handling and storage of data and documents
All patient data are collected into the electronic data
capture platform OpenClinica.
The subjects will be identified using successive num-
bers, generated by the randomisation system. The key to
the code will be maintained by the local investigators in
the Investigator Master File. The coordinating investiga-
tors will receive identifying and contact information for
each participant. This is to enable the coordinating in-
vestigator to retrieve information on outcome events if
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the local investigator does not have this. Participants
consent to this with the informed consent form.
Data will be handled according to the Dutch Personal
Data Protection Act, Good Clinical Practice and other
relevant regulations.
Public disclosure and publication
Results of the described project will be disclosed and
published in peer-reviewed international scientific jour-
nals. If the sponsor and/or the investigators will initiate
a phase III trial based on the results of the present study,
publication of the results of the present trial may be de-
ferred until the results of the phase III trial can be re-
ported. The participant-level dataset will be made
available in a public repository within 5 years after the
publication of the primary report of the study.
Discussion
The APACHE-AF trial is the first trial assessing the
safety and efficacy of one of the DOACs – apixaban – in
a population at risk for both cerebral ischaemia and
bleeding. Data obtained from this trial will be instru-
mental in designing a phase III clinical trial to address
the optimal medical treatment of these patients.
Trial status
Recruitment commenced on 23 September 2014 and the
first patients were included in January 2015.
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